Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1139441

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Technology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to item 9 of NICE’s public board meeting agenda, 17 July 2019, how will membership of the (a) task and finish groups and (b) patient working group be decided; and what opportunities will exist for patient groups not invited to participate with the patient working group.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	277756
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) has advised that membership of the task and finish groups will be decided by the working group. There are three patient/lay representatives on the methods working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Two of the patient/lay representatives also belong to the Patients Involved in NICE coalition.</p><p>NICE has established a dedicated patient working group. There are six patient organisation representatives on the group, including those who belong to the Patients Involved in NICE coalition. The group will work directly with patient/carer groups to coordinate the patient perspective on both methods and process.</p><p>A stakeholder workshop with patient groups was held in January 2019 that included representatives from 22 patient organisations.</p><p>Patient groups will be involved in the review of each of the specific methodological areas as detailed in the paper presented to the NICE board on 17 July 2019. Experts in the area will be invited to participate in topic specific methods task and finish groups.</p><p>Patient organisations will have the opportunity to comment directly on proposals during the public consultation in summer 2020.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 14:24:22 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1139442

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the 2019 Voluntary Scheme for Branded Medicines Pricing and Access, how many opportunities there have been for pharmaceutical industry trade bodies to input into NHS England’s commercial framework; and what steps the Government is taking to secure the participation of industry trade bodies.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	277757
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, are developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</p><p>The commercial framework will support an integrated pricing and access process and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</p><p>In preparation for public consultation in the coming months, NHS England and NHS Improvement are actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 15:46:12 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1139443

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his oral evidence at the Health and Social Care Committee on 9 July 2019, what the expiration date is for the options on the additional transport capacity for medicines; what the timescales are for exercising those options; and what the cost to the Department will be if those options are not exercised.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	277758
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>The details of the contract notices, specification and contract conditions associated with the procurement of contingency freight solutions for medicines and medical products is currently being finalised as part of the pre-procurement market engagement being conducted ahead of publication.</p><p>The terms and conditions associated with the procurement exercises will be available in conjunction with the contract notice publication, to inform potential bidders.</p><p> </p><p> </p><p> </p><p><strong> </strong></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 22/07/2019 15:44:39 answering member 1585 label Biography information for Stephen Hammond
tabling member	4382 label Biography information for Daniel Zeichner

1139444

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his oral evidence at the Health and Social Care Committee on 9 July 2019, if he will place in the Library his Department’s latest assessment of (a) the appropriate level of warehousing capacity required for stockpiling medicines and (b) the flow assumptions of importing medicines in the event that the UK leaves the EU without a deal.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	277759
answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>To ensure sufficient space to store stockpiled medicines, we agreed contracts for additional warehouse space, including ambient, refrigerated and controlled drug storage aligned to the possible 29 March exit date. All these types of storage remain available and should be sufficient to meet the additional needs of medicines suppliers to enable them to build or rebuild their stockpiles prior to 31 October. The original procurement was carried out to give additional leeway should the level of storage required be greater than initially estimated. As part our contingency planning for a possible ‘no deal’ European Union exit on 31 October, we have re-assessed the additional warehouse capacity required to meet the six-week stockpile request made of industry and have confidence that the current capacity we have in place for 31 October will be sufficient.</p><p>The Government’s Border Delivery Group has been reviewing the readiness of border infrastructures and of traders to comply with customs and borders processes in the United Kingdom and the EU. While the predicted flow rate across the short straits has improved slightly since 29 March, significant disruption would be expected for six months following a ‘no deal’ exit, with the most severe period being the first three months.</p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 23/07/2019 15:30:00 answering member 1585 label Biography information for Stephen Hammond
tabling member	4382 label Biography information for Daniel Zeichner

1139445

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the stockpiling of goods for sale at Christmas on warehouse capacity for medicines before the UK leaves the EU on 31 October.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	277760
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>As part our contingency planning for 31 October possible ‘no deal’ European Union exit, we have assessed the additional warehouse capacity required to meet the six-week stockpile request made of industry and have confidence that the capacity we have in place for 31 October will be sufficient.</p><p>Our assessment includes potential seasonal fluctuations in demand for medicines, and the storage is secured through to December so it will not be affected by the additional storage required for Christmas goods.</p><p><strong> </strong></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 22/07/2019 15:46:49 answering member 1585 label Biography information for Stephen Hammond
tabling member	4382 label Biography information for Daniel Zeichner

1131740

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which topics have been identified for inclusion in the upcoming review of the appraisal methods used by NICE.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263870
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263871 263872 263873 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131742

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timescale is for NICE's Methods review.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263871
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263872 263873 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131743

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether changes to NICE’s appraisal methods identified during the NICE Methods review will be cost-neutral.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263872
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263871 263873 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131744

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what criteria was used by NICE to determine which patient organisations were offered membership of the NICE Methods Working Group.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263873
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263871 263872 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131746

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what opportunities there will be for patient groups that are not part of the NICE Methods Working Group to take part in the task and finish groups.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263874
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263871 263872 263873 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner